Editas brings CRIPSR to Wall Street with $94 million IPO
February 3, 2016 – CAMBRIDGE. The gene editing company Editas Medicine debuted on Wall Street after raising $94.4 million in an initial prublic offering. The company sold 5.9 million shares at $16, which valued Editas at roughly $571 million.
Based on its expertise in CRISPR/Cas9 and TALENs technologies, Editas was founded in 2013 with $43 million in Series A venture capital financing led by Flagship Ventures, Polaris Partners and Third Rock Ventures with participation from Partners Innovation Fund.
The company has an enviable list of founders, which includes Jennifer A. Doudna, one of the principal creators of CRISPR and a professor at University of California, Berkeley; George Church, a Founding Member of the Wyss Institute and professor of Genetics at Harvard Medical School; and Feng Zhang, a member of the Broad Institute and professor at the Massachusetts Institute of Technology.